Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that the underwriter of its previously announced underwritten public offering has exercised its option and purchased an additional 70,000 shares of common stock at a price of $40.00 per share
January 29, 2021
· 4 min read